Form 8-K - Current report:
SEC Accession No. 0001326190-24-000027
Filing Date
2024-08-08
Accepted
2024-08-08 07:04:52
Documents
16
Period of Report
2024-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alt-20240808x8k.htm   iXBRL 8-K 43158
2 EX-99.1 alt-20240808xex99d1.htm EX-99.1 172346
3 GRAPHIC alt-20240808xex99d1002.jpg GRAPHIC 7092
  Complete submission text file 0001326190-24-000027.txt   380374

Data Files

Seq Description Document Type Size
4 EX-101.SCH alt-20240808.xsd EX-101.SCH 3267
5 EX-101.LAB alt-20240808_lab.xml EX-101.LAB 18712
6 EX-101.PRE alt-20240808_pre.xml EX-101.PRE 12845
18 EXTRACTED XBRL INSTANCE DOCUMENT alt-20240808x8k_htm.xml XML 4820
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 241185971
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)